Captopril in cardiovascular disease management
- Authors: Terpigorev S.A1, Nikishenkov A.M1, Kabanova T.G1, Zadionchenko V.S2, Yalymov A.A2, Shekhyan G.G2, Shchikota A.M2, Ivanova N.A2, Bogatyrova K.M2
-
Affiliations:
- M.F.Vladimirskiy Moscow Regional Research Clinical Institute
- A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
- Issue: Vol 20, No 1 (2018)
- Pages: 21-26
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/94974
- DOI: https://doi.org/10.26442/2075-1753_2018.1.21-26
- ID: 94974
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
S. A Terpigorev
M.F.Vladimirskiy Moscow Regional Research Clinical Institute
Email: smith@yandex.ru
д-р мед. наук, проф., рук. отд-ния профпатологии и врачебно-трудовой экспертизы 129110, Russian Federation, Moscow, ul. Shchepkina, d. 61/2
A. M Nikishenkov
M.F.Vladimirskiy Moscow Regional Research Clinical Instituteмл. науч. сотр. отд-ния профпатологии и врачебно-трудовой экспертизы 129110, Russian Federation, Moscow, ul. Shchepkina, d. 61/2
T. G Kabanova
M.F.Vladimirskiy Moscow Regional Research Clinical Institute
Email: kabanova75@yandex.ru
канд. мед. наук, науч. сотр. отд-ния профпатологии и врачебно-трудовой экспертизы 129110, Russian Federation, Moscow, ul. Shchepkina, d. 61/2
V. S Zadionchenko
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
Email: z7vladimir@bk.ru
д-р мед. наук, проф., каф. поликлинической терапии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
A. A Yalymov
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
Email: ayalymov@gmail.com
канд. мед. наук, доц. каф. поликлинической терапии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
G. G Shekhyan
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
Email: grant.shekhyan@gmail.com
канд. мед. наук, доц. каф. поликлинической терапии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
A. M Shchikota
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
Email: alexmschikota@mail.ru
канд. мед. наук, доц. каф. поликлинической терапии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
N. A Ivanova
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federationклин. ординатор каф. поликлинической терапии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
K. M Bogatyrova
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federationканд. мед. наук, доц. каф. поликлинической терапии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
References
- Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
- ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesitun sulphate in 58,050 patients with suspected acute MI. Lancet 1995; 345: 669-85.
- Chinese Cardiac Study (CCS-1) Collaborative Group. Oral captopril versus placebo among 14,962 patients with suspected acute MI: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Chin Med J 1997; 110: 834-8.
- Hansson L, Lindholm L.H. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
- Pitt B, Segal R, Martinez F.A et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.
- Pitt B, Poole-Wilson P.A, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
- Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752-60.
- Pfeffer M.A, McMurray J.J.V, Velazquez E.J et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906.
Supplementary files
